Critical Survey: Clarus Therapeutics (OTCMKTS:CRXTQ) and Quince Therapeutics (NASDAQ:QNCX)

Quince Therapeutics (NASDAQ:QNCX) and Clarus Therapeutics (OTCMKTS:CRXTQ) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, analyst recommendations and institutional ownership.

Profitability

This table compares Quince Therapeutics and Clarus Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	-53.27%	-22.73%
Clarus Therapeutics	N/A	N/A	N/A

Insider and Institutional Ownership

30.8% of Quince Therapeutics shares are owned by institutional investors. 16.8% of Quince Therapeutics shares are owned by insiders. Comparatively, 5.3% of Clarus Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Quince Therapeutics and Clarus Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$31.39 million	($1.24)	-1.19
Clarus Therapeutics	N/A	N/A	N/A	N/A	N/A

Analyst Ratings

This is a breakdown of recent ratings and target prices for Quince Therapeutics and Clarus Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	0	0	4	2	3.33
Clarus Therapeutics	0	0	0	0	0.00

Quince Therapeutics currently has a consensus price target of $9.50, suggesting a potential upside of 546.26%. Given Quince Therapeutics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Quince Therapeutics is more favorable than Clarus Therapeutics.

Summary

Quince Therapeutics beats Clarus Therapeutics on 6 of the 8 factors compared between the two stocks.

About Quince Therapeutics

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

About Clarus Therapeutics

Clarus Therapeutics Holdings, Inc., a pharmaceutical company, focuses on the development and commercialization of oral testosterone replacement therapy in the United States. It offers JATENZO, a soft gel oral formulation of testosterone undecanoate for treating hypogonadal men. The company has a licensing agreement with HavaH Therapeutics for product to treat androgen therapies for inflammatory breast disease and certain forms of breast cancer; and license agreement with The Royal Institution for the Advancement of Learning/McGill University to develop and commercialize McGill's proprietary technology designed to treat conditions associated with CoQ10 deficiencies in humans. Clarus Therapeutics Holdings, Inc. was founded in 2003 and is based in Northbrook, Illinois.